LGG-EV regulated intestinal immunity by increasing the CD8 + T/CD4 + T cell ratio in mesenteric lymph nodes and enhancing the ratio of MHC II + DC cells, CD4 + T cells, and CD8 + T cells in tumor tissues. Here, CD8A is linked to neoplasm.